Akebia Therapeutics (AKBA) Net Income towards Common Stockholders (2016 - 2025)
Historic Net Income towards Common Stockholders for Akebia Therapeutics (AKBA) over the last 10 years, with Q3 2025 value amounting to $540000.0.
- Akebia Therapeutics' Net Income towards Common Stockholders rose 10269.47% to $540000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$15.9 million, marking a year-over-year increase of 6541.79%. This contributed to the annual value of -$69.4 million for FY2024, which is 3367.36% down from last year.
- Per Akebia Therapeutics' latest filing, its Net Income towards Common Stockholders stood at $540000.0 for Q3 2025, which was up 10269.47% from $247000.0 recorded in Q2 2025.
- In the past 5 years, Akebia Therapeutics' Net Income towards Common Stockholders ranged from a high of $29.4 million in Q2 2022 and a low of -$83.0 million during Q2 2021
- In the last 5 years, Akebia Therapeutics' Net Income towards Common Stockholders had a median value of -$18.0 million in 2024 and averaged -$25.9 million.
- As far as peak fluctuations go, Akebia Therapeutics' Net Income towards Common Stockholders surged by 13546.45% in 2022, and later plummeted by 381400.65% in 2024.
- Quarter analysis of 5 years shows Akebia Therapeutics' Net Income towards Common Stockholders stood at -$70.4 million in 2021, then surged by 90.76% to -$6.5 million in 2022, then surged by 109.44% to $614000.0 in 2023, then crashed by 3814.01% to -$22.8 million in 2024, then skyrocketed by 102.37% to $540000.0 in 2025.
- Its Net Income towards Common Stockholders stands at $540000.0 for Q3 2025, versus $247000.0 for Q2 2025 and $6.1 million for Q1 2025.